KLRK1 and acute myeloid leukemia: Multiple studies have found that AML patients often have low expression of activating receptors, like NK group 2D (NKG2D), natural cytotoxicity receptors (NCRs), and DNAX accessory molecule‐1 (DNAM‐1), while showing overexpression of inhibitory receptors, such as KIR2DL2/L3 and natural killer group 2A (NKG2A).22, 23, 24